A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
Noemi Lois(Queen's University Belfast), Michael Brines(Northwell Health), Anthony Cerami(Araim Pharmaceuticals (United States)), Rita I. Kirk(Araim Pharmaceuticals (United States)), Christina Campbell(University of Ulster), Evie Gardner(University of Ulster), Ann Dunne(Araim Pharmaceuticals (United States)), Christine McNally(University of Ulster), Nuala Jane Lavery(Queen's University Belfast), Daiva Bajorunas(Araim Pharmaceuticals (United States)), Margaret McFarland(University of Ulster), David Armstrong(University of Southern California)
Cited by 11
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor
|Proceedings of the National Academy of Sciences|2004|654